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Abstract
Introduction Radiographic progression in rheumatoid arthritis
(RA) has in several studies been shown to be predicted by
serological markers widely used in daily clinical practice. The
objective of this longitudinal study was to examine if these
serological markers also predict hand bone mineral density
(BMD) loss in patients with RA of short disease duration.
Methods 163 patients with RA of short disease duration (2.4
years) were included and followed longitudinally. Antibodies to
cyclic citrullinated protein (anti-CCP), rheumatoid factor (RF),
erythrocyte sedimentation rate (ESR), and C-reactive protein
(CRP) were analysed from baseline blood-samples. Hand BMD
was measured by digital X-ray radiogrammetry (DXR) based on
hand and wrist radiographs obtained at baseline and 1, 2 and 5-
year follow-up.
Results During the study period, DXR-BMD decreased by
median (inter quartile range) 1.7% (4.1 to 0.4), 2.8% (5.3 to 0.9)
and 5.6% (11.7 to 2.3) after 1, 2 and 5 years, respectively.
Elevated baseline anti-CCP, RF, ESR and CRP levels were in
univariate linear regression analyses consistently associated
with DXR-BMD change at all time-points. Anti-CCP and ESR
were independently associated with hand DXR-BMD in
multivariate linear regression analyses. Elevated anti-CCP levels
were consistent and independent predictors of loss in cortical
hand bone during the study period, with the odds ratios (95%
confidence interval) 2.2 (1.0 to 4.5), 2.6 (1.1 to 6.2) and 4.9 (1.4
to 16.7) for the 1, 2, and 5-year follow-up periods, respectively.
Conclusions Anti-CCP and ESR were found to be independent
predictors of early localised BMD loss. This finding adds to the
understanding of anti-CCP and ESR as important predictors of
bone involvement in RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
characterised by synovitis and bone destruction. The inflam-
mation in RA causes a shift in the bone metabolism towards
increased osteoclast-mediated bone turn-over [1,2]. This dys-
regulation causes reduced bone mass, which is known to be
an early feature in RA patients, visualised as juxta-articular
bone demineralisation on radiographs [3]. Quantification of
this localised bone loss has been proposed as an outcome
measure in early RA [4]. Measurements of localised bone
involvement in RA can be performed by digital X-ray radio-
grammetry (DXR), which gives an estimate of cortical hand
bone mineral density (BMD) [5,6].
Anti-CCP: antibodies to cyclic citrullinated peptide; BMD: bone mineral density; CRP: C-reactive protein; DMARD: disease-modifying antirheumatic 
drugs; DXR: digital X-ray radiogrammetry; DXR-BMD: hand bone mineral density estimated by digital X-ray radiogrammetry; ELISA: enzyme-linked 
immunosorbent assay; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; Ig: immunoglobulin; IL1: interleukin 1; LSC: least 
significant change; RA: rheumatoid arthritis; RANKL: receptor activator of nuclear factor-kappaB ligand; RF: rheumatoid arthritis; TNFα: tumour necro-
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Early intervention with disease-modifying antirheumatic drugs
(DMARDs), which inhibit joint damage, is accepted as a cor-
nerstone in the treatment strategy of RA [7,8]. Further, the dis-
ease course of RA is heterogeneous and about one-third of
RA patients do not experience joint damage [9,10]. Thus, the
identification of patients prone to bone involvement is impor-
tant at an early stage of the disease in order to individually tai-
lor the RA treatment and optimise disease outcome [1]. DXR
has been shown to measure bone loss in early arthritides and
RA [11]. As a measurement of early bone destruction in RA,
DXR-BMD has also been shown to predict subsequent radio-
graphic damage [12]. Previous studies have shown that sero-
logical biomarkers can predict radiographic damage, a late
measure of bone involvement in RA [13].
The objective of this study was to examine if serological mark-
ers widely used in daily clinical practice also can predict early
involvement of bone measured by DXR in a longitudinal study
of patients with RA of short disease duration.
Materials and methods
Patients
As part of the EURIDISS (European Research on Incapacitat-
ing Disease and Social Support) study, a Norwegian arm of
the cohort was followed longitudinally. At inclusion in 1992,
238 patients aged from 20 to 70 years, with a clinical diagno-
sis of RA and disease duration of less than four years were
included [14]. The patients were assessed at baseline with
blood samples, medical history and health assessment ques-
tionnaire (HAQ). Conventional, bilateral hand and wrist radio-
graphs were taken at baseline and one, two and five-year
follow-up. This article focuses on 163 patients who had radio-
graphs taken at baseline and after one, two or five years follow-
up. Of the 163 patients in this study, 128 had X-rays at all four
time points, 29 at three time points and six patients at two time
points. The patients with and without hand X-rays had similar
baseline characteristics (Table 1). Treatment was given
according to clinical practice. The percentages of patients
who were treated with DMARDs/prednisolone at baseline,
one, two and five years were 53.8/26.3, 46.9/28.1, 50.6/29.4
and 54.9/37.5, respectively. The included patients gave
Table 1
Baseline demographics, treatment and levels of serological biomarkers
Included patients n = 163 Excluded patients n = 75 P value
Demographic variables
Female 75.0 70.5 0.53
Age (years) 53.0 (43.0 to 62.3) 57.0 (43.5 to 64.5) 0.23
Disease duration (years) 2.4 (1.2 to 3.2) 2.5 (1.2 to 3.1) 0.95
HAQ 0.9 (0.4 to 1.4) 1.0 (0.4 to 1.4) 0.60
Treatment
DMARD use 53.8 48.7 0.49
Prednisolone use 26.3 29.5 0.64
Serological biomarkers
ESR (mm/h) 20.0 (10.0 to 38.0) 24.0 (10.5 to 35.5) 0.65
ESR > 20 mm/h 48.5 52.0 0.58
CRP (mg/l) 6.0 (0.0 to 15.0) 7.0 (2.5 to 14.5) 0.36
CRP > 10 mg/l 28.8 26.0 0.66
IgA RF (U/ml) 13.0 (4.0 to 41.3) 17.5 (1.8 to 75.0) 0.56
IgA RF positive 30.2 33.3 0.87
IgM RF (U/ml) 21.0 (5.0 to 105.0) 26.5 (2.0 to 131.0) 0.66
IgM RF positive 41.7 66.7 0.40
Anti-CCP (U/ml) 67.0 (4.4 to 243.0) 56.0 (3.5 to 251.0) 0.82
Anti-CCP positive 60.4 66.7 0.76
The values are given as median (inter quartile range) for continuous variables, percentage for counts.
Anti-CCP = antibodies to cyclic citrullinated peptide; CRP = C-reactive protein; DMARD = disease-modifying antirheumatic drugs; ESR = 
erythrocyte sedimentation rate; HAQ = health assessment questionnaire; Ig = immunoglobulin; RF = rheumatoid arthritis.Available online http://arthritis-research.com/content/11/4/R103
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informed consent and the study was evaluated and approved
by the regional ethics committee.
Laboratory analyses
Erythrocyte sedimentation rate (ESR) was measured by the
Westergren method, ranging from 0 to 140 mm/h. C-reactive
protein (CRP) was measured by phyCardioPhase hs CRP
nephelometry (Dade Behring, Deerfield, Illinois, USA) with a
lowest detectable limit of 0.15 mg/l [9]. Antibodies to cyclic
citrullinated protein (anti-CCP) was analysed by a second gen-
eration ELISA (INOVA Diagnostics Inc, San Diego, CA, USA)
with a range from 0 to 251 U/ml. Values above 25 U/ml were
considered positive. Immunoglobulin (Ig) A and IgM rheuma-
toid factor (RF) were measured by in-house ELISA technique,
ranging from 2 to 300 U/ml and with a positive cut-off at 25 U/
ml [9]. The laboratory analyses used in this study were per-
formed on baseline samples and the measures of CRP, anti-
CCP and RF were performed in frozen sera.
Bone mineral density measurement of the hands
BMD was measured by DXR (Pronosco X-posure 2.0, Sectra,
Linköping, Sweden) based on conventional hand radiographs
from baseline, one, two and five-year follow-up visits. DXR is a
computer version of the traditional radiogrammetry technique
and the method has previously been described in detail [6].
The DXR software automatically recognises the regions of
interest (metacarps two to four) and measures the cortical
thickness, bone width, and bone porosity 118 times per cm.
The precision of the DXR-BMD measurements was calculated
based on duplicate hand radiographs from 28 healthy individ-
uals with repositioning of the hand between each measure.
The coefficient of variation was found to be 0.28%, and the
least significant change (LSC) was 0.79% [12]. Mean values
of both hands were applied to avoid bias regarding dominant
and non-dominant hand and to achieve better precision [15].
Statistical analyses
The analyses were performed using SPSS 14 statistics pack-
age (SPSS, Chicago, IL, USA). The baseline characteristics
had a skewed distribution and were analysed using non-para-
metric methods. Independent groups were compared using
Mann-Whitney U test for continuous variables and chi-squared
tests for dichotomous variables. DXR-BMD change was calcu-
lated as the percentage difference between the follow-up
value and the baseline value. The individual zero to one, one to
two and two to five years changes in DXR-BMD were illus-
trated by cumulative probability plots. DXR-BMD change was
also depicted in probability plots stratified for anti-CCP more
than 25 U/ml and 25 U/ml or less [16]. The distributions of the
soluble biomarkers were skewed (independent variables), and
were therefore for further analyses dichotomised according to
the clinical cut-offs with elevated levels as follows: ESR above
20 mm/h, CRP above 10 mg/l, IgA RF above 25 U/ml, IgM RF
above 25 U/ml and anti-CCP above 25 U/ml.
The associations between the change in DXR-BMD and the
baseline, dichotomised soluble biomarkers were explored by
linear regression analyses. First, univariate linear regression
analyses were performed with one, two and five-year change
in BMD as dependent variables and the dichotomised soluble
biomarkers as independent variables. Further, the independ-
ent variables with a P ≤ 0.25 were included in multivariate lin-
ear analyses. The final multivariate models with only
statistically significant variables were obtained by stepwise
exclusion of the least significant variable from the models and
corrected for age and sex.
Prediction of loss in cortical hand bone was further explored
by logistic regression analyses. Loss in cortical hand bone was
defined as a negative change in DXR-BMD exceeding the
LSC. First, univariate logistic regression analyses were per-
formed with one, two and five-year cortical hand bone loss as
the dependent variable and the baseline, dichotomised sero-
logical biomarkers as independent variables. Secondly, the
independent variables with P ≤ 0.25 were included in multivar-
iate logistic regression analyses. By stepwise exclusion of the
least significant covariate, final models with only statistically
significant variables were obtained and corrected for age and
sex.
All tests were two-sided and P ≤ 0.05 were considered to be
statistically significant. Standard diagnostic tests of model
assumptions and residuals were routinely performed. Residu-
als exceeding three standard deviations were checked for data
errors.
Results
Baseline demographics and soluble biomarkers
Baseline demographics for included and excluded patients
were similar and are summarised in Table 1.
Bone mineral density
DXR-BMD measurements from each examination time point
and DXR-BMD change are presented in Table 2. DXR-BMD
decreased significantly between all time points during the fol-
low-up period (P < 0.05). Median (inter quartile range) DXR-
BMD loss between one and two years, and two and five years
were -1.46% (-1.88 to -1.04) and -3.81% (-4.68 to -2.95; Fig-
ure 1a). Younger women (≤ 50 years) had a trend towards
larger DXR-BMD loss than older women (> 50 years). Median
one, two and five-year DXR-BMD change in younger women
were -2.32%, -3.39% and -7.45% and in older women -
1.15%, -1.73% and -3.88%, respectively. However, this trend
was the same for the men included in the study (data not
shown). DMARD/prednisolone-treated patients had signifi-
cantly larger one, two and five-year DXR-BMD percentage
loss than patients not treated with DMARD/prednisolone; -
2.0/-2.2 vs. -1.1/-1.3, -3.4/-4.1 vs. -1.5/-1.5 and -7.7/-7.8 vs. -
3.3/-3.9, respectively. A loss in cortical hand bone exceeding
the LSC was observed in 66.7%, 77.3% and 89.1% of theArthritis Research & Therapy    Vol 11 No 4    Bøyesen et al.
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Figure 1
Cumulative probability plots presenting the individual patients' change in DXR-BMD Cumulative probability plots presenting the individual patients' change in DXR-BMD. (a) Change in digital X-ray radiogrammetry bone mineral den-
sity (DXR-BMD) of the entire study group (0 to 1 years, 1 to 2 years, 2 to 5 years). (b-d) Change in DXR-BMD stratified according to antibody to 
cyclic citrullinated proteins (anti-CCP) positive/negative patients (empty circle: anti-CCP > 25 U/ml, filled circle: anti-CCP ≤ 25 U/ml) for 0 to 1, 1 to 
2 and 2 to 5 year change, respectively.Available online http://arthritis-research.com/content/11/4/R103
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patients at one, two and five-year follow-up, respectively
(Table 2).
Associations between baseline serological biomarkers 
and change in DXR-BMD
A trend towards larger loss in DXR-BMD in RA patients with
elevated levels of anti-CCP compared with patients with low
levels was observed in cumulative probability plots (Figure 1b
to 1d). Similar trends were seen elevated vs. low levels of ESR,
CRP and RF (data not shown).
Possible associations between DXR-BMD and the serological
biomarkers were explored in linear regression analyses with
DXR-BMD loss as the dependent variable. Elevated baseline
Table 2
DXR-BMD measurements
Baseline (n = 163) One-year follow-up (n = 156) Two-year follow-up (n = 154) Five-year follow-up (n = 138)
DXR-BMD (g/cm2) 0.560
(0.491 to 0.608)
0.545
(0.470 to 0.590)
0.528
(0.458 to 0.586)
0.508
(0.427 to 0.572)
DXR-BMD change (%) † -1.72
(-4.07 to -0.36)
-2.80
(-5.29 to -0.86)
-5.58
(-11.72 to -2.31)
Patients with loss in cortical 
hand bone (%) ‡
66.7 77.3 89.1
Median (inter quartile range) for continuous variables, percentage for counts. Number of patients presented in brackets. DXR-BMD = digital X-ray 
radiogrammetry bone mineral density. † DXR-BMD change from baseline ‡ Decrease in DXR-BMD exceeding the least significant change (least 
significant change = -0.79%).
Table 3
Univariate associations between change in DXR-BMD, baseline characteristics and baseline serological biomarkers (univariate 
linear regression analyses)
One-year change in DXR-BMD (%) Two-year change in DXR-BMD (%) Five-year change in DXR-BMD (%)
B
(95% CI)
P value B
(95% CI)
P value B
(95% CI)
P value
Age (years) -0.1
(-0.1 to 0.0)
0.03 -0.1
(-0.2 to 0.0)
0.002 -0.2
(-0.3 to 0.0)
0.004
Sex (female) -0.1
(-1.4 to 1.2)
0.90 0.6
(-1.3 to 2.4
0.54 0.0
(-3.0 to 3.1)
0.98
Disease duration (years) 0.1
(-0.4 to 0.6)
0.74 0.2
(-0.5 to 0.9)
0.66 0.8
(-0.4 to 1.9)
0.18
HAQ -1.4
(-2.2 to -0.5)
0.003 -1.9
(-3.1 to -0.7)
0.003 -2.3
(-4.5 to -0.2)
0.03
ESR (> 20 mm/h) -2.9
(-4.0 to -1.9)
< 0.001 -4.2
(-5.7 to -2.8)
< 0.001 -6.6
(-9.0 to -4.1)
> 0.001
CRP (> 10 mg/l) -1.6
(-2.8 to -0.3)
0.01 -3.4
(-5.1 to -1.7)
< 0.001 -3.9
(-6.8 to -1.0)
0.008
Anti-CCP (> 25 U/ml) -2.3
(-3.4 to -1.2)
< 0.001 -3.5
(-5.1 to -2.0)
< 0.001 -6.5
(-9.0 to -4.0)
< 0.001
IgA RF (> 25 U/ml) -0.7
(-1.9 to 0.5)
0.26 -2.6
(-4.3 to -1.0)
0.002 -5.0
(-7.6 to -2.3)
< 0.001
IgM RF(> 25 U/ml) -1.2
(-2.3 to -0.1)
0.04 -2.8
(-4.4 to -1.3)
< 0.001 -5.5
(-8.0 to -3.0)
< 0.001
DMARD treatment -1.6
(-2.6 to -0.5)
0.003 -2.6
(-4.3 to -0.9)
0.004 -5.0
(-7.9 to -2.2)
0.001
Prednisolone use -1.0
(-2.2 to 0.1)
0.07 -1.9
(-3.5 to -0.4)
0.02 -3.6
(-6.2 to -1.0)
0.008
Results from univariate linear regression analyses with DXR-BMD as dependent variable.
Anti-CCP = antibodies to cyclic citrullinated peptide; CI = confidence interval; CRP = C-reactive protein; DMARD = disease-modifying 
antirheumatic drugs; DXR-BMD = hand bone mineral density estimated by digital X-ray radiogrammetry; ESR = erythrocyte sedimentation rate; 
HAQ = health assessment questionnaire; Ig = immunoglobulin; RA = rheumatoid arthritis; RF = rheumatoid arthritis.Arthritis Research & Therapy    Vol 11 No 4    Bøyesen et al.
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levels of anti-CCP, RF, ESR and CRP were associated with an
increased one, two and five year DXR-BMD loss in univariate
linear regression analyses (Table 3). Age, HAQ, and DMARD
and prednisolone treatment were also associated with DXR-
BMD loss at all time points (Table 3).
In multivariate linear regression models, elevated levels of anti-
CCP and ESR were independently associated with one-year
loss in DXR-BMD (Table 4). This finding was confirmed in mul-
tivariate regression models with two and five-year DXR-BMD
change as a dependent variable. In addition, elevated baseline
CRP levels and DMARD treatment were independently asso-
ciated with two-year change in DXR-BMD, but not significantly
associated with one and five-year change. Disease duration,
HAQ and prednisolone use did not alter or influence any of the
multivariate models.
Predictors of cortical hand bone loss
Possible predictors of cortical hand bone loss were also exam-
ined using univariate logistic regression models with loss in
cortical hand bone exceeding LSC as the dependent variable.
Elevated baseline levels of anti-CCP and ESR increased the
odds of cortical hand bone loss at one, two and five-year fol-
low-up in univariate logistic regression analyses (Table 5). Fur-
ther, increased odds were observed in high levels of IgA RF for
one and two years of bone loss and elevated IgM and CRP lev-
els for two- and five-year bone loss. In addition, patients with
increased age and HAQ, and DMARD and prednisolone treat-
ment had higher odds of bone loss.
Anti-CCP was a consistent and independent predictor of cor-
tical hand bone loss during the five-year follow-up period in
multivariate logistic regression analyses (Table 6). Elevated
baseline ESR was independently predictive of one- and two-
year cortical hand bone loss. Two-year cortical hand bone loss
was also predicted by prednisolone use.
Discussion
The main finding in this five-year longitudinal study of patients
with RA of short disease duration was that cortical hand bone
loss can be independently predicted by elevated levels of anti-
CCP and ESR. This finding adds to the understanding of anti-
CCP and ESR as important predictors of bone involvement in
RA.
The bone involvement in RA has been shown to start in the
inflamed synovium that express receptor activator of nuclear
factor-κB ligand (RANKL), a cytokine known to mediate oste-
oclast differentiation and activation [1,2]. Expressed in
increased amounts and up-regulated by cytokines such as IL1
and TNFα, RANKL causes the osteoclast to outperform the
osteoblast thus causing increased bone resorption and focal
bone loss. This focal bone loss in RA is seen as a reduction in
trabecular as well as cortical BMD [4,17-19]. In order to target
therapy, prognostic factors of this focal damage should be
Table 4
Independent associations between change in DXR-BMD and baseline serological biomarkers (multivariate linear regression 
analyses)
One-year DXR-BMD change Two-year DXR-BMD change Five-year DXR-BMD change
B
(95% CI)
P value B
(95% CI)
P value B
(95% CI)
P value
Anti-CCP (> 25 U/ml) -1.7
(-2.8 to -0.7)
0.002 -2.1
(-3.5 to -0.6)
0.006 -5.5
(-7.8 to -3.1)
< 0.001
ESR (> 20 mm/h) -2.5
(-3.6 to -1.4)
< 0.001 -3.2
(-4.7 to -1.7)
< 0.001 -5.2
(-7.6 to -2.8)
< 0.001
CRP (> 10 mg/l) -1.8
(-3.4 to -0.3)
0.02
DMARD treatment -1.4
(-2.8 to -0.03)
0.05
Age (years) -0.02
(-0.07 to 0.02)
0.3 -0.05
(-0.1 to 0.002)
0.06 -0.08
(-0.2 to 0.01)
0.09
Sex (female) 0.3
(-0.8 to 1.5)
0.6 0.1
(-0.3 to 2.8)
0.1 0.5
(-2.1 to 3.1)
0.5
Constant 0.5
(-1.9 to 3.1)
0.7 1.8
(-1.5 to 5.1)
0.3 1.8
(-3.6 to 7.2)
0.5
Adjusted R2 21.1% 29.3% 28.5%
Final models after multivariate linear regression analyses. Dependent variable: DXR-BMD change (%).
Anti-CCP = antibodies to cyclic citrullinated peptide; CI = confidence interval; CRP = C-reactive protein; DMARD = disease-modifying 
antirheumatic drugs; DXR-BMD = hand bone mineral density estimated by digital X-ray radiogrammetry; ESR = erythrocyte sedimentation rate.Available online http://arthritis-research.com/content/11/4/R103
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Table 5
Cortical hand bone loss and baseline serological biomarkers (univariate logistic regression analyses)
One-year cortical hand bone loss Two-year cortical hand bone loss Five-year cortical hand bone loss
OR
(95% CI)
P value OR
(95% CI)
P value OR
(95% CI)
P value
Age (years) 1.0
(1.0 to 1.0)
0.15 1.0
(1.0 to 1.1)
0.02 1.1
(1.0 to 1.1)
0.01
Sex (female) 1.3
(0.6 to 2.7)
0.52 2.0
(0.9 to 4.5)
0.09 1.0
(0.3 to 3.5)
0.96
Disease duration (years) 1.0
(0.7 to 1.3)
0.85 1.1
(0.8 to 1.5)
0.69 1.1
(0.7 to 1.7)
0.66
HAQ 1.9
(1.1 to 3.4)
0.03 2.5
(1.3 to 5.0)
0.01 1.5
(0.6 to 3.7)
0.41
ESR (> 20 mm/h) 5.2
(2.4 to 11.1)
< 0.001 5.5
(2.2 to 13.7)
< 0.001 4.6
(1.2 to 17.0)
0.02
CRP (> 10 mg/l) 1.9
(0.9 to 4.1)
0.11 4.1
(1.3 to 12.3)
0.01 6.0
(0.8 to 47.5)
0.09
Anti-CCP (> 25 U/ml) 2.7
(1.4 to 5.5)
0.004 3.2
(1.5 to 7.0)
0.003 5.1
(1.5 to 17.0)
0.01
IgA RF (> 25 U/ml) 2.6
(1.2 to 5.7)
0.01 3.3
(1.3 to 8.5)
0.01 2.2
(0.6 to 8.3)
0.23
IgM RF (> 25 U/ml) 1.7
(0.8 to 3.3)
0.14 3.4
(1.5 to 7.8)
0.005 3.8
(1.0 to 14.2)
0.05
DMARD use 2.1
(1.0 to 4.3)
0.05 2.9
(1.3 to 6.3)
0.009 2.5
(0.8 to 7.4)
0.10
Prednisolone use 2.3
(1.1 to 4.6)
0.02 3.5
(1.5 to 8.1)
0.004 4.8
(1.2 to 17.8)
0.02
Results from univariate logistic regression analyses. Dependent variable: cortical hand bone loss exceeding the least significant change (least 
significant change = -0.79%).
Anti-CCP = antibodies to cyclic citrullinated peptide; CI = confidence interval; CRP = C-reactive protein; DMARD = disease-modifying 
antirheumatic drugs; ESR = erythrocyte sedimentation rate; HAQ = health assessment questionnaire; Ig = immunoglobulin; OR = odds ratio; RF 
= rheumatoid arthritis.
identified. Erosive disease seen in radiographs has across sev-
eral studies been shown to be predicted by anti-CCP, RF,
ESR and CRP [13]. Change in DXA-BMD hand has been
found to be inversely correlated to CRP and RF [18,20]. CRP
has also been found to be associated with one-year hand
DXR-BMD change in the BeST study [21]. In this study we
confirm that RF and CRP are associated with DXR-BMD.
However, in addition we show that elevated levels of anti-CCP
and ESR are independent predictors of DXR-BMD loss. These
common predictors support that erosions and focal bone loss
have a common cellular mechanism.
Use of corticosteroids in high dosages indisputably causes a
wide range of adverse events, including corticosteroid-
induced osteoporosis [22]. Results from studies investigating
the effect of chronic low-dose glucocorticoid use on bone in
RA are conflicting. Although some studies show increased
BMD while using low-dose prednisolone, others show bone
loss [22,23]. In this study the patients using prednisolone took
a daily mean (standard deviation) dosage of 6.5 (2.7) mg, they
were older and had higher HAQ scores than those who did not
(data not shown). With respect to DMARDs influence on
BMD, Schorn and Mowat have demonstrated an increased
cortical thickness in RA patients treated with penicillamine
[24]. Kalla and colleagues have also shown that DMARD treat-
ment increase the cortical bone mass in RA patients [25]. The
DMARD-treated patients in this study had significantly higher
anti-CCP levels than the patients not treated with DMARDs,
indicating a more severe disease. We found that both
DMARDs and prednisolone use was associated with DXR-
BMD loss. RA patients with severe disease are prone to expe-
rience bone loss due to inflammation and immobility, but they
are also more likely to be treated with DMARDs or pred-
nisolone. Therefore, confounding by indication might explain
the associations between DMARD and prednisolone treat-
ment and DXR-BMD loss [26]. We also found age and HAQ
to be associated with increased bone loss. Increased age and
impaired physical function has previously been shown to
explain decreased BMD and might thereby interfere with the
results [27].Arthritis Research & Therapy    Vol 11 No 4    Bøyesen et al.
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A weakness of this study is a lack of available data on impor-
tant factors that influence the BMD. There were no available
data on use of vitamin D, calcium supplements, hormone
replacement therapy or anti-resorptive treatment. Further,
there were no available specifications on the different
DMARDs used during the five-year period. The menopausal
status of the patients was not known. The DXR-BMD loss was
larger in women under 50 years than in those older than 50
years. This might be explained by a rapid bone loss in the
immediate years following menopause. However, this finding
was similar for men, suggesting that menopause did not influ-
ence these results. Another weakness of this study was that
DXA-BMD measurements were not performed. The observed
cortical bone loss could neither be validated against the meas-
ured gold standard DXA-BMD, nor could the observed predic-
tors be validated against trabecular bone loss.
Conclusions
The results of these analyses imply that a hypothetical 40-year-
old female RA patient with elevated levels of ESR and anti-
CCP would at one-year follow-up have a predicted DXR-BMD
loss of 4.2% and an odds of 6.4 for cortical hand bone loss,
compared with a similar patient with normal levels of ESR and
anti-CCP (calculated from the multivariate regression models
presented in Tables 4 and 6). Thus, our findings support that
elevated levels of anti-CCP and ESR are important markers
that have potential impact on the disease course and should
have impact on considerations about treatment strategies in
RA patients. Further, this observation adds support to the
hypothesis of similar mechanisms being involved in hand bone
loss and erosive disease.
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